Clinical Trial Update: Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring imaging staging and response prediction in metastatic hormone-sensitive prostate cancer patients treated with enzalutamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: The European Uro-Oncology Group | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED